0.64
+0.0061(+0.96%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.63 |
| Day High | 0.64 |
| Day Low | 0.62 |
| 52-Week High | 1.42 |
| 52-Week Low | 0.56 |
| Volume | 137,156 |
| Average Volume | 525,600 |
| Market Cap | 26.79M |
| PE | -1.25 |
| EPS | -0.51 |
| Moving Average 50 Days | 0.65 |
| Moving Average 200 Days | 0.81 |
| Change | 0.01 |
If you invested $1000 in SCYNEXIS, Inc. (SCYX) 10 years ago, it would be worth $10.73 as of January 05, 2026 at a share price of $0.639. Whereas If you bought $1000 worth of SCYNEXIS, Inc. (SCYX) shares 5 years ago, it would be worth $87.95 as of January 05, 2026 at a share price of $0.639.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
GlobeNewswire Inc.
Dec 22, 2025 1:00 PM GMT
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has receiv
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
GlobeNewswire Inc.
Nov 19, 2025 12:00 PM GMT
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSE
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
GlobeNewswire Inc.
Nov 17, 2025 3:15 PM GMT
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).Next